Abstract
RUNX1 plays an important role in the regulation of normal hematopoiesis. RUNX1 mutations are frequently found and have been intensively studied in hematological malignancies. Germline mutations in RUNX1 cause familial platelet disorder with predisposition to acute myeloid leukemia (FPD/AML). Somatic mutations of RUNX1 are observed in various types of hematological malignancies, such as AML, acute lymphoblastic leukemia (ALL), myelodysplastic syndromes (MDS), myeloproliferative neoplasm (MPN), chronic myelomonocytic leukemia (CMML), and congenital bone marrow failure (CBMF). Here, we systematically review the clinical and molecular characteristics of RUNX1 mutations, the mechanisms of pathogenesis caused by RUNX1 mutations, and potential therapeutic strategies to target RUNX1-mutated cases of hematological malignancies.
Original language | English (US) |
---|---|
Pages (from-to) | 145-152 |
Number of pages | 8 |
Journal | Molecules and Cells |
Volume | 43 |
Issue number | 2 |
DOIs | |
State | Published - Feb 2020 |
Externally published | Yes |
Keywords
- RUNX1 mutations
- clinical incidence and prognosis
- pathogenesis
- targeted therapy
ASJC Scopus subject areas
- Molecular Biology
- Cell Biology